Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Michael Metzger Sells 7,412 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Michael Metzger sold 7,412 shares of the stock in a transaction on Friday, February 6th. The shares were sold at an average price of $20.62, for a total value of $152,835.44. Following the sale, the chief executive officer owned 508,849 shares in the company, valued at approximately $10,492,466.38. This trade represents a 1.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX opened at $21.01 on Friday. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $22.73. The company’s 50 day simple moving average is $20.67 and its 200 day simple moving average is $16.97. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -5.82 and a beta of 0.46. The company has a debt-to-equity ratio of 2.78, a quick ratio of 4.42 and a current ratio of 4.64.

Wall Street Analyst Weigh In

Several analysts have weighed in on SNDX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. JPMorgan Chase & Co. cut their target price on shares of Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Wall Street Zen raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Syndax Pharmaceuticals in a research report on Monday, October 27th. Finally, BTIG Research restated a “buy” rating and set a $56.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.20.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in SNDX. Pallas Capital Advisors LLC boosted its position in Syndax Pharmaceuticals by 8.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 10,985 shares of the company’s stock worth $231,000 after buying an additional 875 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Syndax Pharmaceuticals by 26.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock valued at $89,000 after acquiring an additional 893 shares during the last quarter. Schroder Investment Management Group lifted its holdings in shares of Syndax Pharmaceuticals by 1.0% during the third quarter. Schroder Investment Management Group now owns 123,404 shares of the company’s stock worth $1,920,000 after purchasing an additional 1,241 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Syndax Pharmaceuticals by 9.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,562 shares of the company’s stock worth $374,000 after purchasing an additional 1,455 shares during the period. Finally, HighTower Advisors LLC grew its stake in shares of Syndax Pharmaceuticals by 8.7% in the fourth quarter. HighTower Advisors LLC now owns 18,940 shares of the company’s stock worth $398,000 after purchasing an additional 1,517 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.